{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 50,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "executive_summary",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a 2x2 grid to summarize program strengths and a timeline for catalysts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/34",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.4,
        "y": 0.75
      },
      "kind": "diagram",
      "text": "Upcoming catalysts timeline: 2H2024 IND/CTN, 1H2025 Human PK/PD",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fe5ccd1-4b82-4bdd-8106-8a56dffed50e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "image",
      "text": "SPY002 antibody illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b14a0747-7639-43fa-8062-b2379c17d32c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.35,
        "y": 0.2
      },
      "kind": "list",
      "text": "Program Summary: Attractive target, Clinically validated pharmacology, Designed for differentiation, Promising early data",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7a228ec-8ffe-438a-9a18-49237c7e5e63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY002 is a potentially best-in-class anti-TL1A mAb with near-term de-risking studies anticipated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d240dc08-af89-4820-a9e1-e4c95e24ac64",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "01b2354e-ba2e-4149-b9f6-85830fb0df03",
      "evidence": "The slide provides a clear and concise program summary, highlighting key points about SPY002.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "18758e45-77fb-4a1b-9ef4-9e16681c548f",
      "evidence": "Upcoming catalysts section shows a chronological progression of milestones.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}